Currently available and approved drugs for the therapy of osteoporosis inhibit bone resorption. Their great clinical value lies in reducing the activity of the osteoclasts and thereby increasing bone mineral density (BMD) and reducing fracture risk. But new bone is not produced and reduction of fracture risk, although highly significant, is rarely more than 50% of the baseline risk level. A different therapeutic approach is osteoanabolic therapy, with stimulation of new bone formation, for which fluoride, strontium ranelate, growth hormone (GH), insulin-like growth factor, the statins and parathyroid hormone (PTH) are the main candidates in humans for short-term administration. However, it should be mentioned that continuously elevated calcium and PTH levels as in primary hyperparathyroidism (pHPT) affect insulin sensitivity and result in increased insulin secretion, but the administration of recombinant human PTH (rhPTH) in the doses given in osteoporosis does not affect glucose homeostasis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Chapter 17 Peptides of the Parathyroid Hormone Family
Anastasilakis A, Goulis D, Polyzos S et al. (2008) Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide. Eur J Endocrinol 158:411–415
Bilezikian J (2008) Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6:24–30
Black D, Greenspan S, Ensrud K et al. (2003) The effect of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215
Bodenner D, Redman C, Riggs A (2007) Teriparatide in the management of osteoporosis. Clin Interv Aging 2:499–507
Boonen S, Marin F, Mellstrom D et al. (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 54:782–789
Canalis E, Giustina A, Bilezikian J (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916
Cosman F, Nieves J, Zion M et al. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566–575
Dempster D, Cosman F, Kurland E et al. (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853
Goltzman D (2008) Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 473:218–224
Greenspan S, Bone H, Ettinger M et al. (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146:326–339
Greenspan S, Bone H, Marriott T et al. (2005) Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP study. J Bone Miner Res 20(Suppl 1):S56
Hodsman A, Bauer D, Dempster D et al. (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703
Jiang Y, Zhao J, Mitlak B et al. (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932–1941
Kaufman J-M, Orwoll E, Goemaere S et al. (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510–516
Miller P (2008) Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep 6:12–16
Neer R, Arnaud C, Zanchetta J et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
Pettway G, Meganck J, Koh A et al. (2008) Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone 42:806–818
Prince R, Sipos A, Hossain A et al. (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513
Rajzbaum G, Jakob F, Karras D et al. (2008) Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 24:377–384
Rosen C, Bilezikian J (2001) Anabolic therapy of osteoporosis. J Clin Endocrinol Metab 86:957–964
Rubin M., Cosman F, Lindsay R, Bilezikian J (2002) The anabolic effect of parathyroid hormone. Osteoporos Int 13:267–277
Stroup J, Kane M, Abu-Baker A (2008) Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 65:532–539
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bartl, R., Frisch, B. (2009). Peptides of the Parathyroid Hormone Family. In: Osteoporosis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79527-8_17
Download citation
DOI: https://doi.org/10.1007/978-3-540-79527-8_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79526-1
Online ISBN: 978-3-540-79527-8
eBook Packages: MedicineMedicine (R0)